Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q1 2019 · 10-Q
Revenue$30.23M$30.23M+245.0% vs Q1 2018 Net Income-$93.08M-$93.08MN/M vs Q1 2018 EPS Diluted-$1.59-$1.59N/M vs Q1 2018 Operating Income-$97,483,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
Free Cash Flowderived-$105,309,000N/M Margins · derivedOperating margin-322.5%+750.4 pt vs Q1 2018
Net margin-307.9%+728.6 pt vs Q1 2018
ended Mar 31, 2019 · filed May 2, 2019 · 32 d after period end